Robert Shorr,


robert shorrAs Chief Scientific Officer of Cornerstone Pharmaceuticals, Dr. Shorr’s primary focus is on the development, human clinical trials, and FDA approvals of safe and effective novel drugs as well as delivery technology for dramatic improvements in cancer disease management.

Dr. Shorr has focused most of his career on the research and discovery of the biochemical basis of neurotransmitter and hormone receptors; their link to metabolic events; their role in pathology, and the design and discovery of therapeutic agents. He has participated in the founding and financing of multiple companies and brought multibillion dollar products to market.

Dr. Shorr’s accomplishments span the spectrum from technological innovation to strategic planning and implementation of research and business development to the founding, financing, and guiding to full commercialization of biotechnology ventures.

Previous to assuming his leadership position at Cornerstone, Dr. Shorr served as Vice President, Science and Technology/Chief Scientist for United Therapeutics/Unither, where he invented PEGylated prostacylcin for pulmonary hypertension. As Vice President of Science and Technology for Enzon Inc., he was responsible for the development and regulatory approval of the blockbuster drug PEG INTRON A, for the treatment of hepatitis and melanoma and contributed to the discovery and development of PEGylated proteins and small molecule drugs.

In addition to serving as Associate Director of the Department of Molecular Pharmacology at SmithKline and French, he is the co-founder and founder, respectively, of Altira Capital and Consulting LLC, and AT Biochem.

Dr. Shorr remains deeply involved in academia and other scientific pursuits. He is a Board member of Brainstorm Cell Therapeutics, Tel Aviv, Israel and has served as Director of Business Development for the University’s Center for Advanced Technology in Biotechnology established by the State of New York at Suny Stony Brook; Chairman of the Scientific Advisory Board at Metabolic Research Inc. and trustee at Tissue Engineering Charities, Inc, the Imperial College of London.

Dr. Shorr has authored more than 250 technical articles, abstracts, book chapters and conference proceedings and has more than 150 inventions and issued or pending patents worldwide. In addition, he has received numerous prestigious awards, including the NJ Cancer Society Gallo Research Award for innovative research in cancer metabolism; Dong Sung Pharmaceutical Award for Drug Delivery; R&D Magazine Innovation Award, and Who’s Who in Science and Innovation. Most recently, Dr. Shorr was appointed as a member of the Scientific Advisory Board for Vyteris, the manufacturer of the first FDA-approved active patch transdermal drug delivery system.

Dr. Shorr received his Ph.D. from the University of London, a D.I.C. from the University of London Imperial College of Science and Technology, and a B.Sc. in Biology from State University of Buffalo.

He is also an ordained Rabbi, having received his Rabbinic ordination from Yeshivat Pirchei Shoshanim, Lakewood NJ and Jerusalem, Israel.

slider bt care differently

slider bt discovery

500 characters left

Know the Science behind

AEMD Platform
Slide item 1

Another Breakthrough
A phase I Study of the Mitochondrial Metabolism Inhibitor CPI-613 in Combination with High Dose Ara-C and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

Slide item 2

People behind the Success

Our Team
Slide item 3